The Economist speaks out on the dangers of using trade agreements to increase patent protections, stating that “America should not use trade deals to swaddle drugmakers in excessive patent protections.” The comments focus on India and the U.S, but could easily be applied to the Canada – EU Trade Agreement.

Cooperation in the Pacific Rim by Jakob Polacsek, World Economic Forum (CC BY-NC-SA 2.0) https://www.flickr.com/photos/worldeconomicforum/48179628441
Digital Trade
Reports Indicate Japan Ratifies ACTA
Reports indicate that Japan has ratified the Anti-Counterfeiting Trade Agreement. Japan had positioned itself as a leading proponent of the treaty, hosting the final round of negotiations and the official signing a year later.
Conservative Chair of International Trade Committee: TPP is Doha-Lite
Rob Merrifield, a Conservative MP and Chair of the Standing Committee on International Trade, has expressed doubts about the Trans Pacific Partnership. Merrifield told iPolitics (sub req) that Canada was unlikely to join the negotiations before the end of the year and likened to talks to the failed WTO Doha […]
NDP Calls for Removal of Patent Provisions from CETA
The NDP has called on the government to remove the patent reform provisions from the Canada – EU Trade Agreement, noting the provisions could add billions in additional health care costs. Earlier this month, I wrote about the concerns with the CETA patent provisions.
Billions at Stake if Canada Caves on Drug Patent Demands
My weekly technology law column (Toronto Star version, homepage version) notes that Canadian negotiators recently advised that there remains a sharp divide over issues such as investment rules, financial services, and taxation. Given the ongoing European financial crisis, these issues are particularly sensitive and will raise questions about how much risk the government is willing to assume in order to strike a deal.
The most contentious issue, however, is likely to be the intellectual property chapter. The revelation that provisions from the Anti-Counterfeiting Trade Agreement may sneak their way into CETA generated widespread headlines throughout Europe last month with politicians and activists expressing exasperation at the clumsy attempt to secretly revive an agreement that was roundly rejected by the European Parliament.
The Canadian opposition to the chapter will come from European demands for patent reforms that could result in billions in additional health care costs due to higher pharmaceutical prices. The pharmaceutical demands are one Europe’s top priorities, but Canada has thus far refused to counter the EU proposals, creating a stalemate that has dragged on for years.